Nonclinical Development of BCG Replacement Vaccine Candidates (original) (raw)
Novel vaccination strategies based on recombinant Mycobacterium bovis BCG
Guido Dietrich
International Journal of Medical Microbiology, 2003
View PDFchevron_right
Recombinant BCG Vaccine Candidates
Mauricio Castañón-arreola
Current Molecular Medicine, 2007
View PDFchevron_right
Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin
Volker Brinkmann
Journal of Clinical Investigation, 2005
View PDFchevron_right
Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis
Stefan Stagliano
Vaccine, 2009
View PDFchevron_right
Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments
Guido Dietrich
Vaccine, 2003
View PDFchevron_right
Engineering new mycobacterial vaccine design for HIV–TB pediatric vaccine vectored by lysine auxotroph of BCG
Pau Ferrer
Molecular Therapy — Methods & Clinical Development, 2014
View PDFchevron_right
Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: Lessons learned
joan joseph
Expert review of vaccines, 2018
View PDFchevron_right
Recombinant Mycobacterium bovis BCG as an HIV vaccine vector
Rosamund Chapman
2010
View PDFchevron_right
A Replication-Limited Recombinant Mycobacterium bovis BCG Vaccine against Tuberculosis Designed for Human Immunodeficiency Virus-Positive Persons Is Safer and More Efficacious than BCG
g harth
Infection and Immunity, 2008
View PDFchevron_right
Recombinant Mycobacterium bovis BCG
Odir Dellagostin, Sibele Borsuk
Vaccine, 2009
View PDFchevron_right
The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing
Mark Cotton
Frontiers in Immunology
View PDFchevron_right
Next-Generation Vaccines Based on Bacille Calmette–Guérin
Natalie Nieuwenhuizen
Frontiers in Immunology, 2018
View PDFchevron_right
A second-generation anti TB vaccine is long overdue
Yolanda López -Vidal
Annals of clinical microbiology and antimicrobials, 2004
View PDFchevron_right
Recent progress in bacterial vaccines: Tuberculosis
Keith McAdam
International Journal of Infectious Diseases, 1997
View PDFchevron_right
A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG
g harth
Vaccine, 2006
View PDFchevron_right
Recombinant BCG approach for development of vaccines: cloning and expression of immunodominant antigens of M. tuberculosis
Anil Tyagi
FEMS Microbiology Letters, 2000
View PDFchevron_right
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis
Sylvie Bertholet
Science translational medicine, 2010
View PDFchevron_right
The Efficacy of the BCG Vaccine against Newly Emerging Clinical Strains of Mycobacterium tuberculosis
Crystal Shanley
PLOS ONE, 2015
View PDFchevron_right
Live recombinant vaccines against tuberculosis that are safer and more potent than BCG
g harth
SciELO Public Health
View PDFchevron_right
SapM mutation to improve the BCG vaccine: genomic, transcriptomic and preclinical safety characterization
Annelies Hecke
2018
View PDFchevron_right
BCG Vaccine and New Tuberculosis Vaccines Against Mycobacterium tuberculosis: A review
Özgül KISA
2020
View PDFchevron_right
Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG Δ ureC :: hly Improves Protection against Tuberculosis
Natalie Nieuwenhuizen
MBio, 2016
View PDFchevron_right
Pre-Clinical Development of BCG.HIVACAT, an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG
joan joseph
PLoS ONE, 2012
View PDFchevron_right
Recent Developments in Mycobacteria-Based Live Attenuated Vaccine Candidates for Tuberculosis
Selvakumar Subbian
Biomedicines
View PDFchevron_right
New use of BCG for recombinant vaccines
Raul Barletta
Nature, 1991
View PDFchevron_right
Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa
Anneke Hesseling
Clinical and vaccine immunology : CVI, 2017
View PDFchevron_right
Molecular Characterization of Heterologous HIV1gp120 Gene Expression Disruption in Mycobacterium bovis BCG Host Strain: A Critical Issue for Engineering Mycobacterial Based-Vaccine Vectors
Joanes Joseph
Journal of Biomedicine and Biotechnology, 2010
View PDFchevron_right
Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine
Babita Agrawal
Frontiers in immunology, 2018
View PDFchevron_right
Enhancing the Protective Efficacy of Mycobacterium bovis BCG Vaccination against Tuberculosis by Boosting with the Mycobacterium tuberculosis Major Secretory Protein
g harth
Infection and Immunity, 2005
View PDFchevron_right
Novel Human In Vitro System for Evaluating Antimycobacterial Vaccines
Brian Eley
Infection and Immunity, 2004
View PDFchevron_right
An Overview of the Development of New Vaccines for Tuberculosis
AbuSalim Mustafa
Vaccines, 2020
View PDFchevron_right